All the news Showing 10 of 17 articles from: Genotype 3Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie Receives Positive CHMP Opinion for MAVIRET® to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis AbbVie press release / 04 February 2020 Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK AbbVie press release / 10 May 2017 U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes Manual Items / 02 November 2015 Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes Gilead press release / 21 September 2015 Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission Bristol-Myers Squibb press release / 15 September 2015 FDA OK's BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3 Manual Items / 27 July 2015 NICE consults on draft guidance recommending ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C NICE / 04 March 2015 Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C Forbes / 09 June 2014 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive